As of March 23, 2026, Acadia Pharmaceuticals's top three insider holders are Bros. Advisors Lp Baker (Director, 39.37Mn shares), Stephen Davis (Ceo, 186.56K shares), Brendan Teehan (Evp, Coo, Head Of Commercial, 62.10K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Stephen Davis | Ceo | 186,555 | 0 | 20 Aug, 2024 |
| Brendan Teehan | Evp, Coo, Head Of Commercial | 62,105 | 0 | 19 Nov, 2024 |
| Srdjan R. Stankovic | President | 61,234 | 0 | 22 Nov, 2022 |
| Mark C. Schneyer | Evp, Chief Financial Officer | 53,338 | 0 | 19 Nov, 2025 |
| Austin D. Kim | Evp,General Counsel, Secretary | 46,901 | 0 | 09 Jan, 2024 |
| Daniel B Soland | 44,041 | 0 | 02 Jun, 2025 | |
| Edmund Harrigan | 35,041 | 0 | 02 Jun, 2025 | |
| Elizabeth A. Garofalo | 25,382 | 0 | 03 Sep, 2025 | |
| James Kihara | Principal Accounting Officer | 25,058 | 0 | 19 Nov, 2025 |
| Adora Ndu | 24,801 | 0 | 02 Jun, 2025 | |
| Laura Brege | 15,095 | 0 | 05 Jun, 2025 | |
| Elena Ridloff | Evp And Cfo | 10,553 | 0 | 30 Apr, 2021 |
| Jennifer J Rhodes | Evp, Chief Legal Officer, Sec | 7,609 | 0 | 10 Feb, 2026 |
| James M Daly | 4,041 | 0 | 12 Nov, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 03 Mar, 2026 | Jonathan Poole | Director Stock Options (Right to Buy) | A | 7,482 | $0.00 | 7,482 | D | A |
| 03 Mar, 2026 | Jonathan Poole | Director Stock Options (Right to Buy) | A | 3,565 | $0.00 | 3,565 | D | A |
| 03 Mar, 2026 | Jonathan Poole | Restricted Stock Units | A | 4,218 | $0.00 | 4,218 | D | A |
| 03 Mar, 2026 | Jonathan Poole | Restricted Stock Units | A | 2,010 | $0.00 | 2,010 | D | A |
| 06 Mar, 2026 | Elizabeth H.Z. Thompson | Stock Option (Right to Buy) | A | 101,574 | $0.00 | 101,574 | D | A |
| 06 Mar, 2026 | James Kihara | Stock Option (Right to Buy) | A | 21,766 | $0.00 | 21,766 | D | A |
| 06 Mar, 2026 | Jennifer J Rhodes | Stock Option (Right to Buy) | A | 90,691 | $0.00 | 90,691 | D | A |
| 06 Mar, 2026 | Mark C. Schneyer | Stock Option (Right to Buy) | A | 90,691 | $0.00 | 90,691 | D | A |
| 06 Mar, 2026 | Thomas Garner | Stock Option (Right to Buy) | A | 97,947 | $0.00 | 97,947 | D | A |
| 06 Mar, 2026 | Adams Catherine Owen | Stock Option (Right to Buy) | A | 263,005 | $0.00 | 263,005 | D | A |
| 06 Mar, 2026 | Thomas Garner | Restricted Stock Units | A | 28,493 | $0.00 | 28,493 | D | A |
| 06 Mar, 2026 | Elizabeth H.Z. Thompson | Restricted Stock Units | A | 29,548 | $0.00 | 29,548 | D | A |
| 06 Mar, 2026 | Jennifer J Rhodes | Restricted Stock Units | A | 26,382 | $0.00 | 26,382 | D | A |
| 06 Mar, 2026 | James Kihara | Restricted Stock Units | A | 6,332 | $0.00 | 6,332 | D | A |
| 06 Mar, 2026 | Adams Catherine Owen | Restricted Stock Units | A | 76,509 | $0.00 | 76,509 | D | A |
| 06 Mar, 2026 | Mark C. Schneyer | Restricted Stock Units | A | 26,382 | $0.00 | 26,382 | D | A |
| 06 Feb, 2026 | Jennifer J Rhodes | Common Stock | A | 12,944 | $0.00 | 14,559 | D | M |
| 09 Feb, 2026 | Jennifer J Rhodes | Common Stock | D | 6,950 | $23.38 | 7,609 | D | S |
| 06 Feb, 2026 | Jennifer J Rhodes | Restricted Stock Units | D | 12,944 | $0.00 | 12,945 | D | M |
| 17 Nov, 2025 | James Kihara | Common Stock | A | 3,966 | - | 25,176 | D | M |